The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IPIG 2025 | Two-year results from the COMMODORE 2 trial of crovalimab in complement inhibitor-naïve PNH
In this video, Richard Kelly, MBChB, PhD, St James’s University Hospital, Leeds, UK, discusses the two-year efficacy and safety data from the Phase III COMMODORE 2 trial (NCT04434092) investigating crovalimab in patients with paroxysmal nocturnal hemoglobinuria (PNH) naïve to complement inhibition. The efficacy of crovalimab was comparable to that of eculizumab; however, crovalimab is a subcutaneous treatment. Dr Kelly notes that this mode of administration offers patients greater freedom and flexibility in managing their disease. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The COMMODORE 2 study is really important in the field of PNH. So patients with hemolytic PNH were randomised either to receive crovalimab or eculizumab in a 2:1 randomisation. There were, I think, 204 patients randomised. And over the two-year period, crovalimab has been shown to be just as efficacious as other anti-complement therapy, well, eculizumab, controlling LDH levels, reducing the need for transfusion support, and the safety profile looks very similar to anti-complement therapies that have already been available...
The COMMODORE 2 study is really important in the field of PNH. So patients with hemolytic PNH were randomised either to receive crovalimab or eculizumab in a 2:1 randomisation. There were, I think, 204 patients randomised. And over the two-year period, crovalimab has been shown to be just as efficacious as other anti-complement therapy, well, eculizumab, controlling LDH levels, reducing the need for transfusion support, and the safety profile looks very similar to anti-complement therapies that have already been available. As it’s a subcutaneous treatment, it allows patients more freedom and flexibility to manage their own disease, which is really important for a lot of patients that we treat, and some patients also have poor venous access and so it gives an extra route of treatment up our sleeves that we can treat patients with.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultant/Advisory board: Alexion, Novartis, Sobi, Roche, Omeros, Florio, Otsuka, Amgen; Speaker fees: Alexion, Sobi, Novartis.
